Article published by Jim O’Donoghue, President of S3 Connected Health on PharmaTimes on 8 May 2019.
Payment-by-outcomes and digital therapeutics (DTx) count among the serious challenges the pharma industry must negotiate in the coming years. They have the potential to change what the healthcare industry reimburses. Rather than a drug alone, it will seek a package of drug, digital services, and digital therapeutics. They will mean digitally-native service providers and DTx firms could start to own relationships with patients - and own patient data too - relegating pharma firms to a smaller physical product partner. But cross-industry collaboration could turn these threats into opportunities.